A Private Placement in a Precision Oncology Platform

​

Targeting a $223 Billion Market. Raising to 1.2 MUSD to advance an AI-driven nanotechnology toward clinical proof-of-concept and a strategic exit.

​

The Opportunity

​

iNANOD is a Norwegian biotechnology company developing a revolutionary AI-driven nanotechnology platform designed to solve the fundamental problem in cancer chemotherapy: low efficacy and high toxicity.

​

By packaging existing and novel cancer drugs into smart nanoparticles, our platform aims to increase drug concentration in tumours from the current industry standard of ~1% to ~20%. This isn't incremental improvement — it's a potential paradigm shift in how chemotherapy is delivered.

​

We are conducting a private placement of up to 1.2 MUSD at a pre-money valuation of 4.8 MUSD for a select group of investors, family offices, and institutional partners.

​​

Note: MUSD stands for Million US Dollar.

​

The Problem We Solve

​

Most cancer therapies fail to deliver their full potential—not because the drugs are ineffective, but because they don’t reach or enter tumours efficiently.

In solid tumours, typically only ~1% of the injected dose accumulates at the target site. Even when drugs arrive, limited internalization and poor cellular uptake significantly reduce therapeutic impact.

This delivery gap remains one of the most critical—and unresolved—challenges in oncology today.

​

Our Solution: Active Targeting, Delivered

​

iNANOD is developing a next-generation drug delivery platform based on engineered stealth liposomes that deliver sufficient drug to solid tumours and ensure it works once it gets there. We are targeting optimization of oncology drugs head-on!

Our approach combines targeting, internalization, and immune activation into a single, coordinated system:

• Precision targeting and uptake
  Monoclonal antibodies guide the stealth liposomes to tumour-specific receptors and actively drive internalization of the therapeutic payload

• Built-in immune activation
  A portion of the antibodies is released within the tumour microenvironment to stimulate a localised anti-tumour immune response

• Enhanced tumor access
  A biological key that triggers a mechanism which improves tumour penetration, increasing the amount of drug that reaches and enters cancer cells.    

 

Built on a clinically validated stealth liposome backbone, our platform extends beyond passive delivery by enabling active, biologically driven tumour targeting and intracellular delivery.

​

By integrating these mechanisms, our system is designed to significantly increase the effective drug concentration inside tumours, addressing the core delivery bottleneck that limits current therapies.

​

The result: a potential step-change in efficacy for solid tumour treatment.

​

Why It Matters?

​

By addressing the delivery bottleneck, our platform has the potential to:

• Increase the fraction of drug reaching tumours (targeting a step-change vs. current ~1%)

• Improve intracellular drug uptake, enhancing therapeutic efficacy

• Combine chemotherapy and immunotherapy effects in a single system

• Unlock new value from existing drugs by making them work better

This creates a platform opportunity across multiple solid malignant tumour indications—not just a single product.

​

​

Why Now? 

​

Several trends are converging to make this the right moment:

​

• Proven biology: monoclonal antibodies and liposomal systems are clinically validated

• Unmet need: solid tumour delivery remains a major limitation despite advances in oncology

• Platform shift: the field is moving from single-mechanism drugs to multi-functional systems

• Translational readiness: iNANOD has completed in silico validation and is advancing toward preclinical proof of principle (PoP).

 

The market is ready for solutions that improve how drugs work—not just what drugs are used.

​

​

​